GH Research PLC (GHRS)

NASDAQ: GHRS · Real-Time Price · USD

21.68

+0.29 (1.36%)

May 18, 2026, 4:00 PM EDT - Market closed

GH Research Earnings Call Transcripts

Fiscal Year 2025

Status Update

GH001 showed rapid, robust, and sustained efficacy in TRD, with a high remission rate and favorable safety profile. Long-term data indicate durable remission with infrequent treatments and fewer clinic visits compared to current standards.

Read full transcript →

Press release

Powered by